Dupixent® late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic for. | May 21, 2023
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic